This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations and is accelerating the development of new and innovative therapies and treatments to improve patient outcomes. The webinar will also cover: The challenges of RWE research and how they are being overcome.
The Indian life sciences sector is making strides by integrating quantum computing, artificial intelligence (AI), machine learning (ML), advanced analytics, bigdata, internet of things (IoT) and blockchain into their research and development efforts.
A recent pharmaphorum webinar , held in partnership with Savana and BREATHE – the Health DataResearch Hub for Respiratory Health, heard that RWE is also accelerating the development of new and innovative therapies and treatments to improve patient outcomes. The benefits of RWE.
If you hadn’t already noticed, the clinicalresearch enterprise has well and truly entered the era of “bigdata,” artificial intelligence (AI), and machine learning. It also includes search and support services that help patients understand, find, and enroll in clinical trials.”
Israel, another leading adopter, has a thriving EHR technology industry that is adapting to the country’s widespread use of BigData from its country’s healthcare systems. Darwin EU is part of the EMA BigData Steering group that aims to increase the utility of BigData in regulatory decision-making.
With approximately one third of all current FDA-approved drugs targeting GPCRs, Verily/Sosei Heptares are looking to expedite GPCR research within not only immunology, but also gastroenterology and immuno-oncology as well, and the latest data bodes well for future development of therapeutic options in these areas.
With more healthcare facilities transitioning from paper charts to electronic records and electronic health records (EHRs) becoming more integrated and technologically advanced, EHRs are expected to drive big changes in the provision of healthcare and clinicalresearch delivery.
Just in time to help recognize Pride Month , ACRP’s ClinicalResearcher journal is pleased to share the first details from the lead peer-reviewed article on “Improving Cardiovascular Research for Transgender and Gender Diverse Populations” from a trio of WCG IRB expert contributors to the new issue going online today (June 13).
Just in time to help recognize Pride Month , ACRP’s ClinicalResearcher journal is pleased to share the first details from the lead peer-reviewed article on “Improving Cardiovascular Research for Transgender and Gender Diverse Populations” from a trio of WCG IRB expert contributors to the new issue going online today (June 13).
Just in time to help recognize Pride Month , ACRP’s ClinicalResearcher journal is pleased to share the first details from the lead peer-reviewed article on “Improving Cardiovascular Research for Transgender and Gender Diverse Populations” from a trio of WCG IRB expert contributors to the new issue going online today (June 13).
Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations and is accelerating the development of new and innovative therapies and treatments to improve patient outcomes.
Pérez-Stable, MD, Director of the National Institute on Minority Health and Health Disparities (NIMHD), shared his thoughts on national priorities for reducing health disparities and opportunities for clinicalresearchers to help promote health equity. He recommended sitting down with people as equals to co-developresearch.
Attendees will learn more about how an SCA was used at the design and execution phases in a recent study of new treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and will also receive an eBook ‘How to harness the potential of AI and real-world data for clinicalresearch’. About the panel.
AI is increasingly important in drug discovery and development as well as clinical trials, operations, pharmacovigilance, and many other areas.” This will also allow companies to utilize advanced computational models to find better treatments more quickly while also reducing costs associated with drug development.
HEPAprint, MEDIKURA, Navro, Embleema & Cloudbyz develop 5 top solutions to watch out for. The Global Startup Heat Map below highlights 5 startups & emerging companies developing pharmacovigilance solutions. Clinical trials play a pivotal role in drug development. Learn more in our Global Startup Heat Map!
As we explore Genmab’s strategic vision, technological advancements and the next frontier in antibody research, we gain insights into the future of medicine — a future where Genmab’s cutting-edge therapies are poised to transform patient care and meet the complex challenges of the next generation of healthcare.
Following its most recent financing round , Massive Bio’s trial enrollment platform has been evolving into a command center to supply research stakeholders with real-time communications, data, and enhanced analytics.
Alongside technical issues, compliance with data protection regulations, pseudo- and anonymisation of data, ethical and legal issues, patient’s consent, and local governmental policies pose additional elements that must be addressed and might differ between the countries, impacting international data sharing.
Rise of the machines – bigdata, AI and machine learning. Companies will capitalise on tech advances in the areas of data use to inform R&D and/or provide personalised care to patients. Patients are beginning to expect the providers of their medicines to help them with their condition and the impact on their lives.
In order to gain marketing approval from regulatory authorities for a novel therapeutic intervention, highly accurate and elaborate clinical trial data is required to validate the drug’s safety and effectiveness towards a specific target indication. Researchers collect data from people and compare changes throughout time.
Although approach differs slightly amongst organizations in clinicalresearch, everyone agrees on this: it’s time for the industry to become more agile. Too many life-saving treatments and medical advancements are at stake to remain attached to the traditional ways of data collection.
International deep real-world evidence company Savana is on a mission to give health researchers the power to unlock the clinical value embedded within electronic health records (EHRs) using artificial intelligence (AI) and clinical Natural Language Processing (NLP) techniques. About Savana.
This is a relatively new model of clinical trials in terms of adoption and is, therefore, the highly underutilized method of conducting clinicalresearch. What are the Benefits of Virtual Clinical Trial Solutions/ Decentralized Clinical Trial Solutions?
There has never been a time when rapid, low burden access to patient-level data, at scale, was more urgent.
rows of data. Syntegra has also engaged with the Federal Drug Administration (FDA) to evaluate the role of synthetic data in regulatory decisions, for COVID-19 and beyond.
.
The clinical trials landscape is evolving more rapidly than ever before. Meanwhile, decentralisation and the BigData revolution are transforming the way researchers run clinical trials, and previously untapped geographies are emerging as new hubs for future research. of the global trial landscape.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content